

# AACI CCAF ANNUAL MEETING

CHICAGO 2018

September 30 – October 2, 2018

LOEWS CHICAGO DOWNTOWN HOTEL



Association of  
American Cancer Institutes

3708 Fifth Avenue  
Medical Arts Building, Suite 503  
Pittsburgh, PA 15213

Phone: 412-647-6111

[www.aaci-cancer.org](http://www.aaci-cancer.org)



ASSOCIATION OF AMERICAN CANCER INSTITUTES

CME jointly provided by the American Association for Cancer Research  
and the Association of American Cancer Institutes.



# Table of Contents

---

- 1 **Welcome**
- 2 **Program Committee**
- 3 **Agenda**
- 14 **Continuing Medical Education**
- 16 **Awardee Profiles**
- 18 **Exhibitors**
- 22 **Disclosure of Financial Relationships**
- 24 **CME Worksheet**
- 25 **Support**

## Wireless Internet and Presentation Information

Wireless network (SSID): **AACI**

Password: **aaci2018**

To access the 2018 AACI/CCAF Annual Meeting documents please visit <http://portal.aaci-cancer.org>

The email login is [events@aaci-cancer.org](mailto:events@aaci-cancer.org) and the password is **aaci2018**

# Welcome

---

**E**xpert perspectives on the future of cancer research and care, including the latest on CAR T-cell therapy, Big Data management, and international partnerships, are among the highlights of the 2018 joint annual meeting of the Association of American Cancer Institutes (AACI) and the Cancer Center Administrators Forum (CCAF).

The meeting convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies. The three-day event focuses on exploring solutions to common challenges and sharing best practices.

This year's meeting will mark two major leadership transitions for AACI. Roy A. Jensen, MD, director of The University of Kansas Cancer Center, will become the association's new president and will introduce his presidential initiative, which aims to develop a comprehensive, cancer-specific clearinghouse of model legislation for AACI cancer centers to share with their state legislators. In addition, this will be my final annual meeting as I will be retiring later this month after 19 years as AACI's first executive director. Jennifer W. Pegher, who has served for six years at AACI as director of government relations and deputy director, will succeed me as AACI's new executive director.

This year's annual meeting program, jointly formulated by AACI and CCAF, begins with a panel discussion by four distinguished cancer center leaders who will share their insights and predictions for how academic cancer centers will evolve over the next decade. Special guests include Ned Sharpless, MD, who will be addressing the annual meeting for the first time as director of the National Cancer Institute. Awardees this year are Charles M. Perou, MD, who will receive the AACI Distinguished Scientist Award, and Richard and Susan Rogel, who will be honored with AACI's first Champion for Cures Award for their transformational philanthropy at the University of Michigan Rogel Cancer Center.

No other event provides information on cancer research and patient care issues as they pertain to academic cancer center leaders, and provides them with a forum to discuss common issues. On behalf of the 2018 AACI/CCAF Annual Meeting Program Committee, welcome to the Windy City!

Sincerely,

Barbara Duffy Stewart, MPH  
*AACI Executive Director*

# Program Committee

**Chair: Randall F. Holcombe, MD, MBA**

University of Hawai'i Cancer Center  
University of Hawai'i at Mānoa

**Michael J. Bertram, PhD, MBA**

UAB Comprehensive Cancer Center  
University of Alabama at Birmingham

**Peter Connor, MS**

University of Wisconsin  
Carbone Cancer Center

**B. Mark Evers, MD**

UK Markey Cancer Center

**Seanne Falconer, MBA, FACHE**

Masonic Cancer Center  
University of Minnesota

**Stanton L. Gerson, MD**

Case Comprehensive Cancer Center

**Roy A. Jensen, MD**

The University of Kansas Cancer Center

**Candace S. Johnson, PhD**

Roswell Park Comprehensive Cancer Center

**Karen E. Knudsen, PhD**

Sidney Kimmel Cancer Center at  
Jefferson Health

**Carrie Lee, MD, MPH**

UNC Lineberger  
Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

**Malcolm Moore, MD**

BC Cancer

**Timothy L. Ratliff, PhD**

Purdue University  
Center for Cancer Research

**Thomas A. Sellers, PhD, MPH**

Moffitt Cancer Center

**Barbara Duffy Stewart, MPH**

Association of American Cancer Institutes

# Agenda

All sessions will be held in the Wright Ballroom, Lobby Level, except where indicated.

## Sunday, September 30

**11:00 am Meeting Registration Begins**

Wright Foyer, Lobby Level

**11:00 am Exhibits Open**

Wright Foyer, Lobby Level

**12:00 pm Welcome and AACI Business Meeting**

**President's Report**

**Dr. Stanton L. Gerson**

Case Comprehensive Cancer Center

**Executive Director's Report**

**Ms. Barbara Duffy Stewart**

Association of American Cancer Institutes

**Treasurer's Report**

**Mr. Jeff Walker**

City of Hope National Medical Center

**Program Chair's Report**

**Dr. Randall F. Holcombe**

University of Hawai'i Cancer Center

University of Hawai'i at Mānoa

**CCAF Report**

**Mr. David M. Gosky**

UK Markey Cancer Center

**1:00 pm A 10-Year Outlook for Academic Cancer Centers**

Academic cancer centers have made remarkable strides in recent years that have enhanced their ability to deliver better care to patients, from the increased availability of genomic information sequencing to advances in the areas of targeted therapy, immunotherapy, and cancer screening technology. To help centers sustain that progress and build on their decades of learning, speakers in this session will share their perspectives and predictions for how academic cancer centers will evolve over the next 10 years. Topics of conversation will include maintaining research and managing innovation; distributed care; changes in reimbursement and points of care; and use of electronic methods of care delivery.

All 2018 AACI/CCAF Annual Meeting sessions will be held in the Wright Ballroom, Lobby Level, except where indicated.

# Agenda

## Sunday, September 30

**Moderator: Dr. Stanton L. Gerson**

Case Comprehensive Cancer Center

**Dr. Steven T. Rosen**

City of Hope Comprehensive Cancer Center

**Dr. Michael B. Kastan**

Duke Cancer Institute  
Duke University Medical Center

**Dr. Candace S. Johnson**

Roswell Park Comprehensive Cancer Center

**2:00 pm New President's Initiative**

**Dr. Roy A. Jensen**

The University of Kansas Cancer Center

**2:15 pm Networking Break**

**2:45 pm Cancer is a Global Issue: Partnerships with the Developing World**

A growing number of cancer centers have established partnerships with countries in the developing world, with involvement extending to both research and the direct delivery of care. This session will include an overview of cancer research and treatment in the developing world, as well as details about how centers are interacting with specific countries including Kenya, Malawi, and Cuba, where U.S. sanctions are creating unique challenges for cancer research collaborations.

**Moderator: Dr. Malcolm Moore**

BC Cancer

**Dr. Jack Welch**

National Cancer Institute

**Dr. Satish Gopal**

UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

**Dr. Dan Namarika**

Ministry of Health, Malawi

**Dr. Patrick J. Loehrer**

Indiana University Melvin & Bren Simon Cancer Center

**Dr. Kelvin P. Lee**

Roswell Park Comprehensive Cancer Center

**4:00 –  
6:00 pm**

**6th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting**

**Avoiding Physician Burnout: Strategies for Promoting Personal and Professional Satisfaction**

Whether diagnosing cancer or managing related complications, devising personalized treatment plans, providing critical support in the face of daunting illness, or myriad other intellectually and emotionally stimulating tasks, caring for cancer patients can be immensely rewarding. Despite its rewards, caring for cancer patients can also be a stressful calling. From life and death decision-making to keeping pace with constantly evolving science, productivity requirements, and regulatory and administrative burdens, oncology practice takes its toll physically and emotionally. In this session, panelists will discuss the professional and personal consequences associated with physician burnout and will suggest strategies for avoiding downturns and promoting personal and professional satisfaction.

**Moderator: Dr. Randall F. Holcombe**

University of Hawai'i Cancer Center  
University of Hawai'i at Mānoa

**Dr. Fay J. Hlubocky**

The University of Chicago Medicine Comprehensive Cancer Center

**Dr. Daniel McFarland**

Memorial Sloan Kettering Cancer Center

**Dr. Ronald M. Epstein**

Wilmot Cancer Institute  
University of Rochester Medical Center

**4:30 –  
5:30 pm**

**CCAF Business Meeting**

(closed session for members of CCAF)  
Sullivan Ballroom A, Lobby Level

**6:00 –  
7:30 pm**

**Welcome Reception — Sponsored by Forte**

Garden Terrace, Third Floor

# Agenda

## Monday, October 1

**7:00 am** **General Breakfast**  
Sullivan Ballroom BC, Lobby Level

**7:00 am** **Exhibits Open**  
Wright Foyer, Lobby Level

**8:00 am** **AACI Presidential Initiative Update: Network Care**  
Managing cancer center networks is a complex task involving many moving parts; without a clear roadmap, a network can become unmanageable. AACI's Network Care Initiative aims to help AACI's academic cancer centers paint an accurate picture of their impact on cancer care across the regions they serve. AACI President Dr. Stanton Gerson will provide an update on the initiative, including a summary of final survey results. This session will cover topics related to network management, including standardization of care and the use of care paths (suggested diagnostic and treatment pathways); collaborating with other centers and community sites; working with varied employment network models; and providing access to clinical trials.

**Moderator: Dr. Stanton L. Gerson**  
Case Comprehensive Cancer Center

**Dr. Michael E. Kupferman**  
University of Texas MD Anderson Cancer Center

**Dr. Ravi Salgia**  
City of Hope Comprehensive Cancer Center

**8:45 am** **Concurrent Session**  
**How to Get the Most Out of Your External Advisory Board (EAB)**

Wright Ballroom, Lobby Level

When immersed in the day-to-day challenges of managing a cancer center, it can be easy to develop tunnel vision and lose sight of the big picture. A fresh perspective can help identify areas for improvement that may have been overlooked. As part of the CCSG renewal process, National Cancer Institute (NCI)-Designated Cancer Centers are required to host site visits and demonstrate success in carrying out meritorious science. To prepare for renewal, cancer centers invite external advisory boards (EAB) to visit their cancer centers and provide detailed critiques. In this session, panelists will discuss best practices for selecting and inviting experts to join a cancer center's EAB, how to set expectations before a site visit, and the unique ways AACI cancer centers utilize this essential resource.

**Moderator: Mr. Peter Connor**  
University of Wisconsin Carbone Cancer Center

**Dr. Karen Knudsen**  
Sidney Kimmel Cancer Center at Jefferson Health

**Ms. Lauren Hackett**  
Vanderbilt-Ingram Cancer Center

**Dr. Michelle M. Le Beau**  
The University of Chicago Medicine Comprehensive Cancer Center

**Mr. David M. Gosky**  
UK Markey Cancer Center

**8:45 am** **Concurrent Session**  
**Big Data in Cancer Care**  
Sullivan Ballroom, Lobby Level

As Big Data changes the face of cancer research and treatment, the vast amount of information—and wide variety of sources for that information—are presenting significant challenges in collecting and integrating data. This session convenes commercial and academic players in the Big Data arena with an eye toward enhancing dialogue and developing stronger linkages that could lead to expanded information-sharing and improved patient care.

**Moderator: Dr. Thomas A. Sellers**  
Moffitt Cancer Center

**Ms. Cindy Terrano**  
Moffitt Cancer Center

**Dr. Kerin Adelson**  
Yale Cancer Center  
Yale School of Medicine

**Dr. John Sweetenham**  
Huntsman Cancer Institute  
University of Utah

**10:00 am** **Break**

# Agenda

## Monday, October 1 *continued*

### 10:15 am **Cancer Health Economics**

In the face of persistent shifts in the political landscape and health care marketplace, cancer centers are confronting an expanding array of funding and reimbursement challenges. Speakers in this session will discuss emergent issues such as understanding policies governing coverage for gathering genomic sequencing data and other innovative therapies, caring for underserved patients, and the latest developments at the Centers for Medicare and Medicaid Services.

**Moderator: Dr. Randall F. Holcombe**

University of Hawai'i Cancer Center  
University of Hawai'i at Mānoa

**Dr. K. Robin Yabroff**

American Cancer Society

**Dr. Stuart Peacock**

BC Cancer

**Dr. Rena M. Conti**

Boston University Questrom School of Business

### 11:30 am **2018 AACI Distinguished Scientist Award Quantitative Medicine for Breast Cancer Patients**

Charles M. Perou, PhD, a renowned breast cancer researcher at the UNC Lineberger Comprehensive Cancer Center, is being recognized by AACI for his accomplishments in the field of precision medicine and for groundbreaking research in the characterization of the diversity of human tumors. The clinical value of his work leading to the discovery of the intrinsic subtypes of breast cancer has had a profound impact on the treatment of breast cancer patients worldwide. Dr. Perou's talk will focus on sequencing studies for gene expression analysis; specifically, on research results showing the value of sequencing-based approaches in breast and lung cancers.

**Dr. Charles M. Perou**

UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

### 12:30 pm **AACI Awards Lunch**

Sullivan Ballroom, Lobby Level

#### 2018 AACI Champion for Cures Award

**Richard and Susan Rogel**

### 1:30 pm **Networking, CRI Posters, and Dessert — Sponsored by Florence**

Wright Foyer, Lobby Level

### 2:00 pm **2018 Election Update**

(session not CME accredited)

With the 2018 election just weeks away, Mr. Frommer will discuss the midterm elections, highlighting retirements and toss-ups and the impact the winners might have on cancer centers. He will also discuss the prospects for funding for the NIH in this and the next Congress.

**Mr. Ross A. Frommer**

Columbia University Irving Medical Center

### 2:15 pm **AACI Clinical Research Initiative (CRI) Update**

In July, AACI's CRI convened its 10th annual meeting with the program theme "Leveraging Change to Advance Cures for Cancer Patients." The meeting provided an opportunity for clinical trials office (CTO) administrative and medical directors, representatives from industry, corporate roundtable members, and others to network, share best practices, and begin conversations that can lead to more effective cancer treatments. During this session, Dr. Lee will highlight CRI's progress and growth over the past year—this year's meeting drew a record 405 attendees and more than 60 poster submissions—as well as goals for 2019. She will also present preliminary results from the CRI benchmarking survey, which captured data on CTO workload, structure and staffing, trial activation timeline, and sources of CTO funding support at AACI cancer centers.

**Dr. Carrie Lee**

UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

### 2:45 pm **Comprehensive Cancer Patient Support**

Just as a spouse, children, relatives, and friends offer invaluable support to a loved one with cancer, cancer centers are increasingly recognizing the value to patients of a support network of experts drawn from fields as disparate as mental health, geriatric care, pain and symptom management, survivorship, and counseling for financially challenged patients. Over time, the field has transformed from palliative care and alternative medicine to an expansive array of research interests and treatment approaches that underpin nearly all cancer center operations. Panelists will explore programs that cancer centers have developed to enhance comprehensive support and deliver multidisciplinary care for the patient with cancer.

**Moderator: Dr. Donald L. Rosenstein**

UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

**Dr. Judith A. Paice**

Robert H. Lurie Comprehensive Cancer Center  
Northwestern University

# Agenda

## Monday, October 1 *continued*

### **Dr. Smita Bhatia**

UAB Comprehensive Cancer Center  
University of Alabama at Birmingham

### **Dr. Steven R. Patierno**

Duke Cancer Institute  
Duke University Medical Center

### **4:00 pm Break**

### **4:15 pm Concurrent Session CCSG Nuts and Bolts**

Wright Ballroom, Lobby Level

Optimal compliance with NCI Cancer Center Support Grant (CCSG) guidelines will be explored in this session, with particular focus on selected cancer centers that have recently completed core grant submissions. The practical implications of preparing a CCSG competing renewal will be reviewed, and advice will be offered regarding different approaches for freestanding versus matrix cancer centers.

### **Moderator: Mr. Alex Zafirovski**

Robert H. Lurie Comprehensive Cancer Center  
Northwestern University

### **Ms. Donna Berrier**

Hollings Cancer Center  
Medical University of South Carolina

### **Mr. Dale Henry**

Roswell Park Comprehensive Cancer Center

### **Ms. Melissa Fitzmaurice Neligan**

UCLA Jonsson Comprehensive Cancer Center

### **4:15 pm Concurrent Session Tumor Microenvironment**

Sullivan Ballroom, Lobby Level

The tumor microenvironment is a complex network of cells and extracellular matrix proteins that support tumor development and progression. As we move toward personalized medicine in cancer care, understanding the influence of structural entities on gene expression and communication among functionally distinct, but phenotypically identical, cells within the environment is essential to effectively translating individualized therapy to patients.

This session will focus on the impact of matrix rigidity on gene expression by the multiplicity of cells in the tumor microenvironment. The session will also highlight the impact of single cell genomics and transcriptomics and its potential to impact patient care.

### **Moderator: Dr. B. Mark Evers**

UK Markey Cancer Center

### **Dr. Vadim Backman**

Robert H. Lurie Comprehensive Cancer Center  
Northwestern University

### **Dr. Paul Robson**

The Jackson Laboratory Cancer Center

### **5:30 pm Sessions End**

### **8:30 – 11:00 pm Hospitality Suite — Sponsored by Complion**

ETA Restaurant, Lobby Level

## Tuesday, October 2

### **7:00 am General Breakfast**

Sullivan Ballroom BC, Lobby Level

### **7:00 am Topic-Specific Breakfast Roundtable Discussions**

Sullivan Ballroom A, Lobby Level

#### **Advice For Your First CCSG**

### **Ms. Seanne Falconer**

Masonic Cancer Center  
University of Minnesota

#### **Career Enhancement**

### **Dr. John Crispino**

### **Mr. Alex Zafirovski**

Robert H. Lurie Comprehensive Cancer Center  
Northwestern University

#### **Data Collection for Community Outreach and Engagement**

### **Dr. Michael J. Bertram**

UAB Comprehensive Cancer Center  
University of Alabama at Birmingham

#### **So You Want to be Designated?**

### **Mr. David M. Gosky**

UK Markey Cancer Center

### **Dr. Robert Mannel**

Stephenson Cancer Center  
University of Oklahoma

# Agenda

**Tuesday, October 2** *continued*

## Introduction to PCLI

**Dr. Randall F. Holcombe**

University of Hawai'i Cancer Center

University of Hawai'i at Mānoa

## Follow-up on the CRI Benchmarking Survey

**Ms. Janie Hofacker**

Association of American Cancer Institutes

## 7:00 am Exhibits Open

Wright Foyer, Lobby Level

## 8:00 am NCI Director's Report

The director of the NCI will highlight programmatic priorities and identify funding opportunities to support ongoing collaborations between the NCI and academic cancer centers.

**Dr. Norman E. Sharpless**

National Cancer Institute

## 8:45 am Guidelines-Driven Review: Conveying Comprehensiveness, Training, and Community Engagement

As cancer centers continue to wrestle with revised guidelines for the NCI's CCSG application, some metrics that help to determine funding levels are proving problematic. Panelists will discuss comprehensiveness, training, and community engagement, with an eye toward clarifying definitions, NCI's perspective and expectations, and factors that drive the scoring of centers' performance in these areas.

**Moderator: Dr. Roy A. Jensen**

The University of Kansas Cancer Center

**Dr. Randall F. Holcombe**

University of Hawai'i Cancer Center

University of Hawai'i at Mānoa

**Dr. Cory Abate-Shen**

Herbert Irving Comprehensive Cancer Center

Columbia University Medical Center

**Dr. Michael Teitell**

UCLA Jonsson Comprehensive Cancer Center

## 9:45 pm Break

## 10:00 am Best Practices in Cell Therapy/CAR T

The FDA granted its first approvals for CAR T-cell therapy in 2017. In these early days of cellular therapy and other forms of adoptive cell transfer, more cancer centers are stepping up their efforts in the field. Among the decisions being weighed are whether to develop cells in-house, procure them from commercial entities, or embrace a hybrid approach. Panelists will consider that issue as well as the nuts and bolts of developing a CAR T-cell therapy program, including intake and management issues, standard operating procedures, financial challenges, and regulatory requirements.

**Moderator: Dr. Joseph McGuirk**

The University of Kansas Cancer Center

**Dr. Lihua Elizabeth Budde**

City of Hope Comprehensive Cancer Center

**Dr. Stephan A. Grupp**

Children's Hospital of Philadelphia

**Mr. Richard P. Bondi**

UPMC Hillman Cancer Center

## 11:00 am Update on the NCI Cancer Centers Program

This session provides an opportunity for an open dialogue with the director of the NCI Office of Cancer Centers about the requirements and funding of the CCSG.

**Dr. Henry P. Ciolino**

National Cancer Institute

## 11:45 am Adjourn

# Continuing Medical Education

---

## Joint Providership Statement

Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

---

## Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

---

## Credit Designation

The American Association for Cancer Research designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

---

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

---

## Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)<sup>™</sup> for this live continuing medical education activity must complete the CME Request for Credit Survey by November 5, 2018. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

---

## Learning Objectives

Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program's learning objectives, all attendees should be able to describe and discuss:

- The evolution of the academic cancer center in the next decade
  - The value of bi-directional partnerships from both the clinical and research perspective in the global cancer enterprise
  - Strategies for promoting both the clinical and research perspective in the global cancer enterprise
  - Models of care across cancer center networks which promote efforts to integrate treatment services into the community
  - Best practices for assembling an external advisory board (EAB)
  - Ways to collect and integrate data with an eye toward expanded information-sharing and improved care for the cancer patient
- 

# Continuing Medical Education

---

- Strategies for navigating the changing health care marketplace
  - The value of sequencing based approaches in breast and lung cancers
  - Progress of the AACI Clinical Research Initiative (CRI) over the last decade
  - Programmatic models which enhance comprehensive patient support and care
  - Compliance with the most current NCI CCSG guidelines
  - The impact of matrix rigidity on gene expression by the multiplicity of cells in the tumor microenvironment
  - Challenges and opportunities for collaboration among academia, government, and the private sector
  - Various aspects of compliance with the NCI CCSG guidelines with a focus on comprehensiveness, training, and community engagement
  - Developing a CAR T-cell therapy program with an emphasis on intake and management issues, standard operating procedures, and regulatory requirements
  - NCI's priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to academic cancer centers
- 

## Americans with Disabilities Act

It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact 412-647-6111 or attach a note to your registration form.

---

## Faculty Disclosure

It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

---

## Target Audience

This transdisciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects. All attendees have a significant impact on cancer research and patient care.

Attendees may include:

- Leaders of AACI's academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical staff
- Leaders from industry and government agencies as well as those of cancer research and advocacy organizations
- Medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, and psychologists
- Social workers, cancer communication specialists, public health leaders, and faculty members who focus on cancer

## Awardee Profiles

---

### 2018 AACI Distinguished Scientist Award



**Dr. Charles M. Perou**  
**UNC Lineberger Comprehensive Cancer Center**

Charles M. Perou, PhD, is the May Goldman Shaw Distinguished Professor of Molecular Oncology at UNC Lineberger Comprehensive Cancer Center. He is also the faculty director of UNC Lineberger's Bioinformatics Group, co-director of its Breast Cancer Research Program, and a professor in its Genetics and Pathology & Laboratory Medicine departments. His research interests span the disciplines of cancer biology, genomics, genetics, bioinformatics, statistics,

systems biology, and the treatment of cancer patients in the clinic.

AACI's award recognizes Dr. Perou's research accomplishments in the field of precision medicine and his groundbreaking research in the characterization of the diversity of human tumors. The clinical value of Dr. Perou's work leading to the discovery of the intrinsic subtypes of breast cancer has profoundly impacted the treatment of patients with breast cancer worldwide. In addition, his lab has successfully created computational predictors of complex cancer phenotypes, which will ultimately have clinical application.

After the award presentation, Dr. Perou will deliver a talk focused on sequencing studies for gene expression analysis, specifically, on research results showing the value of sequencing-based approaches in breast and lung cancers.

A faculty member at UNC since 2000, Dr. Perou has authored more than 330 peer-reviewed articles and has filed to protect five patents in the United States and Europe. He earned his bachelor's degree in biology from Bates College, his doctorate in cell biology from University of Utah, and performed his postdoctoral work in the laboratory of Dr. David Botstein (then at Stanford University).

Previous AACI Distinguished Scientist honorees are Drs. Carl June, James Allison, Lewis Cantley, Tim Ley, Brian Druker, Lee Hartwell, Mary-Claire King, Janet Rowley, Stuart Schreiber, Bert Vogelstein, Robert Weinberg, and Irving Weissman.

## Awardee Profiles

---

### 2018 AACI Champion for Cures Award



**Richard and Susan Rogel**

The Association of American Cancer Institutes (AACI) has established the Champion for Cures Award to recognize individuals who demonstrate significant leadership in supporting efforts to cure cancer and in inspiring others to do the same. The inaugural award will be presented to Richard and Susan Rogel in recognition of their \$150 million gift to the University of Michigan Comprehensive Cancer Center, which was renamed Rogel Cancer Center in their honor.

The gift is the largest ever to Michigan Medicine and one of the largest in the University of Michigan's history. It will support cancer research by funding endowed professorships, competitive research grants, and scholarships, and by establishing a collaborative network that will bring international experts to the University of Michigan for six to 12 months to develop innovative new projects.

Having contributed \$188.5 million to at least 17 different areas across the University of Michigan, the Rogels are the second largest individual donors in university history. They made their first major gift in 1987.

The Rogels' lives have been touched extensively by cancer. Mr. Rogel, a U-M alum, lost his father to pancreatic cancer. Both of Mrs. Rogel's parents died of cancer, and her 50-year-old daughter, Ilene, died five years ago from an aggressive form of lung cancer.

The Rogels live in Avon, Colorado, and Scottsdale, Arizona. Mr. Rogel serves as president of the investing firm Tomay Inc. A native of New Jersey, he is the founder, former chairman, and CEO of the Preferred Provider Organization of Michigan, which was the first in the country of this type of health insurance plan. In the late 1990s, he sold it to Blue Cross Blue Shield of Michigan.

# Exhibitors

---

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

## Complion

The need for efficiency and standardization in clinical research has never been greater. Lack of standardization, manual processes, and teams working in technology silos make study management a major challenge.

At Complion, we see massive opportunities for increased efficiency and productivity. Our goal is to transform an institution's regulatory environment into one driven by standards and consistency. That's why we developed the first 21 CFR Part 11 compliant Electronic Regulatory (eRegulatory) system designed specifically for clinical research sites.

Our purpose-built eRegulatory system for research sites and organizations aims to:

- Ensure comprehensive trial documentation, with fewer incomplete or missing documents
- Improve version control across teams to ensure all documents are up to date and in one location
- Standardize processes and automate workflows to ensure adherence to SOPs
- Identify quality metrics to inform operations and process improvements
- Achieve audit-readiness and 21 CFR 11 compliance

## Florence

Florence advances clinical trials through software for managing document and data flow between research sites and sponsors. Florence eBinders is trusted by 3,000+ researchers for eRegulatory, eSource, and contract management, and Florence eHub is revolutionizing site-sponsor connectivity in a shared workspace for startup, monitoring, and quality control.

## Forte

Forte provides clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems to unleash their research potential. With a strong belief in community collaboration and standards-based development, Forte also facilitates the Onsemble Community, a customer-exclusive group for peer networking, best practices, and support. Twice a year at the Onsemble Conference, clinical research professionals meet in person and discuss the latest challenges and solutions in clinical research. Forte provides all research professionals complimentary blog articles, eBooks, webinars, and more to support continuous learning on industry topics.

## GuideStar Research

GuideStar Research works with hospitals, health systems, and academic medical centers around the country to build and support clinical research programs. From helping organizations develop or refine a clinical trial strategy to providing support for coverage analysis, regulatory start-up, contracts, budgets, and more, our experienced team helps to ensure optimal results for research programs.

## Huron

Huron is a global consultancy that helps our clients drive growth, enhance performance, and sustain leadership in the markets they serve. We partner with them to develop strategies and implement solutions that enable the transformative change our clients need to own their future. Learn more at [www.huronconsultinggroup.com](http://www.huronconsultinggroup.com).

## M2Gen

M2Gen® is a health informatics solutions company focused on accelerating the discovery and development of personalized medicines. M2Gen partners with the nation's leading cancer centers through the Oncology Research Information Exchange Network (ORIEN) to create a large, cancer focused data warehouse linking clinical and molecular data. Using this information, M2Gen helps biopharmaceutical companies address the greatest challenges in oncology drug development. Founded in 2006, M2Gen operates the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. Through ORIEN, cancer centers serve more patients by sharing and collaboration. To date, more than 250,000 Total Cancer Care® consented patients have agreed to donate their tissue and clinical data for research to understand cancer at the molecular level. For more information, visit [www.M2Gen.com](http://www.M2Gen.com).

## Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs, and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease, and infectious diseases including HIV and Ebola. For more information, visit [www.merck.com](http://www.merck.com) and connect with us on Twitter, Facebook, Instagram, YouTube, and LinkedIn.

## OnLive

OnLive is the official website for the Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, and Oncology Nursing News. The mission of OnLive and these publications is to provide oncology professionals with the resources and information they need to provide the best patient care. OnLive is also home to the Peer Exchange and Insights video editorial series, which provides a unique opportunity to view lively discussions with authoritative insights, opinions, and perspectives on important issues facing today's cancer care professionals.

We cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. OnLive allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds,

# Exhibitors

---

blogs, and live coverage from major oncology meetings. As we move ahead, we will continually look for new and better ways to get you oncology news as quickly and efficiently as possible. It is an exciting time for cancer research and treatment, and we look forward to being Your Link to Everything Oncology.

## Patient Resource

Patient Resource's innovative, advanced patient education, navigation and reporting platform provides hospitals and cancer centers with the tools to guide and track each cancer patient from the first appointment, throughout treatment, and on to survivorship. Guides, uniquely developed for each patient, include specific diagnosis and treatment care plans. Our personal, one-to-one, patient app provides medication adherence set-up as well as tracking options for self-reported outcomes. The system itself includes powerful administrative reporting and cost analysis tools and offers process standardization for all clinics.

## PFS Clinical

PFS Clinical is dedicated to helping research institutions improve the management of their clinical trials from study start-up to final payment. Our research administration experts and collaborative service lines—Initiate, Revenue Guard, and Boost Consulting—support institutions through the various stages of clinical trials. Based on the needs of your institution, Initiate teams provide on-demand study initiation services for contracts, budgets, coverage analyses, and CTMS calendar builds. With Revenue Guard, our experienced research billing specialists can manage your billing processes with services including financial tracking, reconciliation, and reporting, and claims review, allowing you to focus on patient outcomes. Boost Consultants collaborate with your team to improve your research programs through meaningful process redesign, CTMS implementation, org. chart and SOP development, and flexible education and training. If you're looking for a partner to be an extension of your research team, look to PFS Clinical. For more information, please visit [www.pfsclinical.com](http://www.pfsclinical.com) or email [questions@pfsclinical.com](mailto:questions@pfsclinical.com).

## Society for Immunotherapy of Cancer

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals across the globe dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word "cure" a reality for cancer patients everywhere. Learn more about SITC at [sitcancer.org](http://sitcancer.org) and follow us on Twitter, LinkedIn, Facebook, and YouTube.

## Takeda Oncology

Takeda Oncology is dedicated to developing and delivering novel medicines to cancer patients worldwide through our science, innovation, and passion. Our legacy includes therapies for hematologic cancers and solid tumors, including lung cancer. We aspire to cure cancer.

## TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a nonprofit organization dedicated to improving the health of people around the world by simplifying and accelerating the research and development (R&D) of innovative new therapies. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry and examine solutions for addressing common challenges.

TransCelerate brings together R&D leaders from biopharmaceutical companies, research sites, clinical research organizations, regulatory authorities, and patient-focused organizations to develop solutions to common drug development issues and drive efficiencies into the R&D process. TransCelerate is proud to lead a progressive agenda that advances innovation in R&D. In the coming years, we will continue to challenge ourselves and take on new initiatives that we believe will improve the investigator and patient experience, encourage data-sharing as appropriate, reduce cost and process inefficiencies, and improve quality.

## Velos

Velos is the trusted, comprehensive clinical research management software company for cancer centers, academic medical centers, hospital chains, national health systems, and other clinical research organizations and sponsors in the U.S. and internationally. For over fifteen years, Velos' core mission has been to facilitate efficiency, quality and compliance in the field of clinical research with a particular focus on research at cancer centers. Our experience and vision is that a comprehensive approach to addressing clinical research information needs can unlock a wealth of value in both productivity and medical discovery. Anchored by the flagship Velos eResearch CRMS, the Velos product line supports study and protocol management, electronic data capture, financial management, protocol review and IRBs, patient recruitment, drug accountability, biospecimen management, and more. The company enables its customers to organize across multiple sites and research collaborators, remain 21 CFR Part 11 compliant, and integrate with key third party systems. Velos is privately held with headquarters in Fremont, California. For more information, please visit [www.velos.com](http://www.velos.com).

# Disclosure of Financial Relationships

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.

*Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock Shareholder; SB, Speakers' Bureau; H, Honoraria; O, Other.*

Last Name	First Name	Member Name	Relationships	Type	Role
Abate-Shen	Cory	Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center	No Relationships		Speaker
Adelson	Kerin	Yale Cancer Center, Yale School of Medicine	No Relationships		Speaker
Anderson	Jaime	Association of American Cancer Institutes	No Relationships		Program Committee
Backman	Vadim	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	No Relationships		Speaker
Berrier	Donna	Hollings Cancer Center, Medical University of South Carolina	No Relationships		Speaker
Bertram	Michael	UAB Comprehensive Cancer Center, University of Alabama at Birmingham	No Relationships		Program Committee, Speaker
Bhatia	Smita	UAB Comprehensive Cancer Center, University of Alabama at Birmingham	No Relationships		Speaker
Bondi	Richard	UPMC Hillman Cancer Center	No Relationships		Speaker
Budde	Lihua Elizabeth	City of Hope Comprehensive Cancer Center	Precision Bioscience, Mustang Therapeutics	A,G	Speaker
Ciolino	Henry	National Cancer Institute	No Relationships		Speaker
Connor	Peter	University of Wisconsin Carbone Cancer Center	No Relationships		Program Committee, Speaker
Conti	Rena	Boston University Questrom School of Business	No Relationships		Speaker
Crispino	John	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	No Relationships		Speaker
Epstein	Ronald	Wilmot Cancer Institute University of Rochester Medical Center	No Relationships		Speaker
Evers	B. Mark	UK Markey Cancer Center	No Relationships		Program Committee, Speaker
Falconer	Seanne	Masonic Cancer Center, University of Minnesota	No Relationships		Program Committee, Speaker
Frommer	Ross	Columbia University Irving Medical School	No Relationships		Speaker
Gerson	Stanton	Case Comprehensive Cancer Center	No Relationships		Program Committee, Speaker
Gopal	Satish	UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill	No Relationships		Speaker
Gosky	David	UK Markey Cancer Center	No Relationships		Speaker
Grupp	Stephan	Children's Hospital of Philadelphia	Novartis, TCR2 Therapeutics, Eureka Therapeutics, Adaptimmune	A	Speaker
Hackett	Lauren	Vanderbilt-Ingram Cancer Center	No Relationships		Speaker
Henry	Dale	Roswell Park Comprehensive Cancer Center	No Relationships		Speaker
Hlubocky	Fay	The University of Chicago Medicine Comprehensive Cancer Center	No Relationships		Speaker
Hofacker	Janie	Association of American Cancer Institutes	No Relationships		Program Committee
Holcombe	Randall	University of Hawai'i Cancer Center, University of Hawai'i at Mānoa	Merck	C	Program Committee, Speaker
Jensen	Roy	The University of Kansas Cancer Center	No Relationships		Program Committee, Speaker
Johnson	Candace	Roswell Park Comprehensive Cancer Center	No Relationships		Program Committee, Speaker
Kastan	Michael	Duke Cancer Institute Duke University Medical Center	Aileron Therapeutics, XRad Therapeutics	A,O	Speaker
Knudsen	Karen	Sidney Kimmel Cancer Center at Jefferson Health	Cell Centric, Celgene, Janssen, Novartis, Sanofi, Sanofi-Aventis	C, G, SB	Program Committee, Speaker
Kupferman	Michael	University of Texas MD Anderson Cancer Center	No Relationships		Speaker
Le Beau	Michelle	The University of Chicago Medicine Comprehensive Cancer Center	UpToDate	O	Speaker
Lee	Carrie	UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill	No Relationships		Program Committee, Speaker
Lee	Kelvin	Roswell Park Comprehensive Cancer Center	No Relationships		Speaker
Loehrer	Patrick	Indiana University Melvin & Bren Simon Cancer Center	No Relationships		Speaker
Mannel	Robert	Stephenson Cancer Center, University of Oklahoma	No Relationships		Speaker
McFarland	Daniel	Memorial Sloan Kettering Cancer Center	No Relationships		Speaker
McGuirk	Joseph	The University of Kansas Cancer Center	Kite Pharma, Novartis, Fresenius Biotech, Astellas Pharma, Bellicum Pharmaceuticals	G, H, SB	Speaker
Moore	Malcolm	BC Cancer	No Relationships		Program Committee, Speaker
Namarika	Dan	Ministry of Health, Malawi	No Relationships		Speaker
Neligan	Melissa Fitzmaurice	UCLA Jonsson Comprehensive Cancer Center	No Relationships		Speaker
Paice	Judith	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	No Relationships		Speaker
Patierno	Steven	Duke Cancer Institute, Duke University Medical Center	AstraZeneca	G,O	Speaker
Peacock	Stuart	BC Cancer	No Relationships		Speaker
Perou	Charles	UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill	BiodClassifier, LLC, GeneCentric Therapeutics	A,C,S	Speaker
Ratliff	Timothy	Purdue University Center for Cancer Research	No Relationships		Program Committee
Robson	Paul	The Jackson Laboratory Cancer Center	No Relationships		Speaker
Rosen	Steven	City of Hope Comprehensive Cancer Center	No Relationships		Speaker
Rosenstein	Donald	UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill	Oxford University Press, UpToDate	O	Speaker
Salgia	Ravi	City of Hope Comprehensive Cancer Center	No Relationships		Speaker
Sellers	Thomas	Moffitt Cancer Center	No Relationships		Program Committee, Speaker
Sharpless	Norman	National Cancer Institute	G1 Therapeutics, Healthspan Diagnostics, Unity Biotechnology, Pfizer	A,C,H,O,S	Speaker
Stewart	Barbara Duffy	Association of American Cancer Institutes	No Relationships		Program Committee, Speaker
Sweetenham	John	Huntsman Cancer Institute, University of Utah	Seattle Genetics	H	Speaker
Teitell	Michael	UCLA Jonsson Comprehensive Cancer Center	No Relationships		Speaker
Terrano	Cindy	Moffitt Cancer Center	No Relationships		Speaker
Walker	Jeff	City of Hope National Medical Center	No Relationships		Speaker
Welch	Jack	National Cancer Institute	No Relationships		Speaker
Yabroff	K. Robin	American Cancer Society	No Relationships		Speaker
Zafirovski	Alex	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	No Relationships		Speaker

# CME-Approved Sessions Worksheet

Date	Time	Session Title	Approved Credits	Claimed Credits
Sunday 9/30/18	1:00 – 2:00 pm	A 10-Year Outlook for Academic Cancer Centers	1.0	
	2:00 – 2:15 pm	New President's Initiative	0.25	
	2:45 – 4:00 pm	Cancer is a Global Issue: Partnerships with the Developing World	1.25	
	4:00 – 6:00 pm	6th Annual AACI PCLI Meeting: Avoiding Physician Burnout	2.0	
		<b>Maximum Approved Credits for 9/30/18</b>	<b>4.5</b>	<b>TOTAL:</b>
Monday 10/1/18	8:00 – 8:45 am	AACI Presidential Initiative Update: Network Care	0.75	
	8:45 – 10:00 am	How to Get the Most Out of Your EAB (concurrent)	1.25	
		Big Data in Cancer Care (concurrent)		
	10:15 – 11:30 am	Cancer Health Economics	1.25	
	11:30 am – 12:30 pm	Quantitative Medicine for Breast Cancer Patients	1.0	
	2:15 – 2:45 pm	AACI Clinical Research Initiative (CRI) Update	0.50	
	2:45 – 4:00 pm	Comprehensive Cancer Patient Support	1.25	
4:15 – 5:30 pm	CCSG Nuts and Bolts (concurrent)	1.25		
	Tumor Microenvironment (concurrent)			
		<b>Maximum Approved Credits for 10/1/18</b>	<b>7.25</b>	<b>TOTAL:</b>
Tuesday 10/2/18	8:00 – 8:45 am	NCI Director's Report	0.75	
	8:45 – 9:45 am	Guidelines-Driven Review: Conveying Comprehensiveness, Training, and Community Engagement	1.0	
	10:00 – 11:00 am	Best Practices in Cell Therapy/CAR T	1.0	
	11:00 – 11:45 am	Update on the NCI Cancer Centers Program	0.75	
		<b>Maximum Approved Credits for 10/2/18</b>	<b>3.5</b>	<b>TOTAL:</b>
		<b>Maximum CME Credits Approved</b>	<b>15.25</b>	<b>TOTAL:</b>

# Support

## Acknowledgment of Commercial Support

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Astellas
- AstraZeneca
- Cejka Executive Search
- Flatiron
- Foundation Medicine
- Genomic Health
- Huron Consulting Group
- Lilly
- Merck
- Novartis
- Pfizer

## Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Complion
- Florence
- Forte
- Genentech
- Gilead
- Janssen Research & Development
- Lilly
- Merck
- Pfizer
- Takeda Oncology
- Velos

Support as of September 12, 2018

## 2019 Meetings — Save the Date

---

## Notes

---



**AACI CRI**  
Clinical Research Initiative

**July 10-11, 2019** • Loews Chicago O'Hare Hotel



**AACI ANNUAL MEETING** **CCAF MEETING**  
WASHINGTON, DC 2019

**October 20-22, 2019** • Mayflower Hotel